Immunocore Aims For $100m IPO After Immunotherapy Success
Proof-Of-Concept For TCR platform
Executive Summary
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.
You may also be interested in...
Immunocore and Argenx Among Fast-Track Hopefuls At EMA
EU reviewers will decide this week whether to grant accelerated assessment to a handful of new dug candidates that will soon be filed for approval.
Finance Watch: Ten IPOs In Three Days Raise $1.9bn
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
UK Biotechs Look Destined To Remain Bit Players
Another promising British-based company, GW Pharma, has been acquired, this time by mid-sized US player Jazz. Is it a pipedream that a UK biotech could be in a position to pull off a $7bn takeover of its own or does it really not matter?